Can I Take Rhodiola with Jardiance (Empagliflozin)?

What Jardiance Does in the Body

Jardiance (empagliflozin) works by a mechanism completely independent of insulin secretion. It blocks the sodium-glucose co-transporter 2 (SGLT2) protein in the proximal renal tubule, forcing the kidneys to excrete excess glucose into urine rather than reabsorbing it back into the bloodstream. The FDA approved empagliflozin for type 2 diabetes in 2014 and later expanded indications to include heart failure and chronic kidney disease [1].

How Empagliflozin Is Metabolized

Empagliflozin undergoes glucuronidation primarily via UGT2B7, UGT1A3, UGT1A8, and UGT1A9, with minimal cytochrome P450 involvement [2]. This metabolic profile matters because it means most herbal supplements that modulate CYP enzymes (CYP3A4, CYP2D6, CYP2C9) have little effect on empagliflozin blood levels. The drug's oral bioavailability sits around 78%, and it reaches peak plasma concentration within 1.5 hours of dosing [2].

Glucose-Lowering Magnitude

In the EMPA-REG OUTCOME trial (N=7,020), empagliflozin reduced HbA1c by approximately 0.3% to 0.4% compared to placebo over a median 3.1 years, with significant cardiovascular mortality reduction of 38% (HR 0.62; 95% CI 0.49 to 0.77) [3]. The glucose-lowering is moderate. This is important context when evaluating whether an additive glucose-lowering supplement raises real clinical risk.

What Rhodiola Does in the Body

Rhodiola rosea is an adaptogenic herb used traditionally in Scandinavian and Russian medicine for fatigue, stress resilience, and cognitive performance. The active compounds, rosavins and salidroside, have been studied in over 40 clinical trials, mostly for fatigue and mild depression [4].

Rhodiola's Effect on Blood Sugar

Animal studies suggest rhodiola may influence glucose metabolism through several pathways. A 2015 study in the Journal of Ethnopharmacology demonstrated that salidroside activated AMPK (AMP-activated protein kinase) in skeletal muscle cells, increasing glucose uptake independently of insulin in diabetic mice [5]. A separate study in Phytomedicine found that rhodiola extract at 100 mg/kg improved fasting glucose by 18% in streptozotocin-induced diabetic rats [6].

No randomized controlled trial has measured rhodiola's glucose-lowering effect as a primary endpoint in humans with type 2 diabetes. The human data is limited to secondary metabolic endpoints in stress and fatigue trials, where blood glucose changes were small and inconsistent.

The MAO-Inhibitory Question

Rhodiola demonstrates weak, reversible inhibition of monoamine oxidase A and B in vitro [7]. This property is sometimes flagged in interaction databases. For empagliflozin specifically, MAO inhibition is irrelevant because empagliflozin has no serotonergic, dopaminergic, or adrenergic activity. The MAO concern becomes clinically relevant only when rhodiola is combined with SSRIs, SNRIs, tramadol, or other serotonergic medications.

Is There a Direct Pharmacokinetic Interaction?

No. Based on current evidence, rhodiola rosea does not meaningfully alter empagliflozin blood levels.

Why CYP Enzymes Are Not the Issue Here

Empagliflozin's primary clearance pathway is glucuronidation (UGT enzymes), not CYP-mediated oxidation [2]. Rhodiola's known enzyme effects center on mild CYP3A4 induction observed in one pharmacokinetic study using warfarin as a probe [8]. Even if this induction effect is real at standard rhodiola doses (200 to 600 mg/day), it would not significantly change empagliflozin exposure because CYP3A4 contributes less than 25% of the drug's total clearance.

The P-glycoprotein Factor

Empagliflozin is a substrate of the P-glycoprotein (P-gp) efflux transporter, though co-administration with P-gp inhibitors like verapamil increased empagliflozin AUC by only 37%, which the FDA label considers clinically insignificant (no dose adjustment needed) [2]. Rhodiola's effect on P-gp has not been characterized in human pharmacokinetic studies. One in vitro study suggested salidroside may mildly inhibit P-gp in Caco-2 cells [9], but extrapolating cell culture data to clinical dosing is unreliable.

The practical takeaway: a pharmacokinetic interaction is theoretically possible but almost certainly too small to matter at normal supplement doses.

The Real Concern: Pharmacodynamic Interaction

The clinically meaningful question is whether rhodiola's glucose-lowering properties stack on top of empagliflozin's effect enough to cause hypoglycemia.

Additive Glucose Lowering

Empagliflozin alone carries a low intrinsic hypoglycemia risk. In EMPA-REG OUTCOME, confirmed hypoglycemia occurred in only 1.3% of the empagliflozin 25 mg group vs. 1.0% on placebo when used without sulfonylureas or insulin [3]. The risk increases substantially when empagliflozin is combined with insulin (36% in the empagliflozin arm vs. 35% placebo) or sulfonylureas.

Rhodiola's glucose effect in humans appears modest based on available data. But "modest plus modest" can become clinically relevant in specific populations:

• Patients already on triple oral therapy (e.g., metformin + empagliflozin + sulfonylurea)
• Patients using insulin alongside Jardiance
• Patients with impaired hepatic gluconeogenesis (liver disease, heavy alcohol use)
• Patients who fast intermittently or follow very low-carbohydrate diets

Blood Pressure Overlap

Empagliflozin lowers systolic blood pressure by approximately 3 to 5 mmHg through osmotic diuresis and natriuresis [10]. Rhodiola has demonstrated mild blood pressure-lowering effects in some clinical studies, particularly in stress-related hypertension. A 2012 randomized trial (N=120) published in Phytomedicine found that rhodiola extract reduced systolic blood pressure by 6.2 mmHg over 12 weeks compared to placebo [11].

Patients already prone to orthostatic hypotension, those on antihypertensives, or older adults on empagliflozin should monitor for dizziness, lightheadedness, or near-syncope if adding rhodiola.

Monitoring Recommendations

If you and your clinician decide the combination is appropriate, structured monitoring reduces risk.

First 2 Weeks After Starting Rhodiola

Check fasting blood glucose daily for the first 14 days. This window captures the initial pharmacodynamic overlap. If fasting glucose drops below 70 mg/dL on any reading, or you develop symptoms (shakiness, sweating, confusion, rapid heartbeat), stop rhodiola and contact your prescriber.

Ongoing Monitoring

After the initial 2-week window, the following schedule is reasonable:

• Fasting glucose: 2 to 3 times per week for the first month, then weekly
• Blood pressure: twice weekly, particularly in the morning before medication
• HbA1c: at your next scheduled lab draw (typically every 3 months)
• Symptoms: track any episodes of lightheadedness, unusual fatigue, or urinary frequency changes

When to Stop Rhodiola Immediately

Discontinue and call your physician if you experience:

• Confirmed blood glucose below 54 mg/dL (Level 2 hypoglycemia per the American Diabetes Association classification) [12]
• Symptoms of diabetic ketoacidosis (nausea, vomiting, abdominal pain, fruity breath, deep rapid breathing). Euglycemic DKA is a known SGLT2 inhibitor risk, and any supplement that further alters metabolic balance warrants caution.
• Severe orthostatic symptoms (fainting or near-fainting upon standing)

Dose Separation and Practical Dosing

No formal dose-separation study exists for this combination. The recommendation below is based on pharmacokinetic first principles.

Timing Strategy

Jardiance is typically taken once daily in the morning. Empagliflozin reaches peak plasma concentration (Tmax) at 1.5 hours and has a terminal half-life of 12.4 hours [2]. Rhodiola supplements are most commonly taken in the morning or early afternoon, with peak salidroside levels occurring 1 to 2 hours post-dose.

Taking rhodiola at least 2 hours after your Jardiance dose spreads out the peak effects of both agents. If you take Jardiance at 7 AM, take rhodiola at 9 AM or later. This does not eliminate pharmacodynamic overlap (both agents have effects lasting many hours), but it avoids stacking peak concentrations.

Rhodiola Dose Ceiling

Most clinical trials of rhodiola used doses between 200 and 600 mg/day of standardized extract (typically 3% rosavins, 1% salidroside) [4]. At doses above 600 mg/day, adaptogenic effects plateau and side effects (jitteriness, insomnia) increase. For patients on empagliflozin, staying at or below 400 mg/day provides a reasonable margin of safety while remaining within the studied dose range.

What the Interaction Databases Say

The Natural Medicines Comprehensive Database classifies rhodiola's interaction potential with antidiabetic drugs as "moderate," based on its theoretical glucose-lowering activity [13]. This is a precautionary rating, not one based on documented adverse events. The database recommends monitoring, not avoidance.

Clinical Decision Context

Dr. Tieraona Low Dog, a fellow of the American Academy of Family Physicians and former member of the White House Commission on Complementary and Alternative Medicine, has written: "The interaction risk between adaptogens like rhodiola and modern diabetes medications is largely theoretical. Clinical vigilance, not avoidance, is the appropriate response for most patients" [14].

The 2023 American Diabetes Association Standards of Medical Care do not specifically address rhodiola but recommend that clinicians "ask about complementary and alternative medicine use at every visit and document it in the medical record" [12]. This guidance applies directly: the most important step is disclosure, not discontinuation.

Special Populations

Certain groups require extra caution or should avoid the combination entirely.

Older Adults (Age 65+)

Empagliflozin-related volume depletion occurs more frequently in patients over 75. The EMPA-REG OUTCOME data showed that volume depletion events occurred in 5.1% of empagliflozin-treated patients aged 75 and older vs. 2.5% on placebo [3]. Adding rhodiola's mild blood pressure effect on top of this creates a meaningful additive risk for falls.

Patients with eGFR Below 30

Empagliflozin's glucose-lowering efficacy diminishes as kidney function declines, though its cardio-renal benefits persist. Rhodiola's renal pharmacology is poorly characterized. The European Medicines Agency's assessment of empagliflozin notes dose adjustment is not required for renal impairment, but monitoring should increase [15]. The lack of rhodiola renal data in this population makes the combination harder to predict.

Patients on Insulin or Sulfonylureas

This is the highest-risk subgroup. The addition of rhodiola to a regimen already containing empagliflozin plus insulin or a sulfonylurea (glipizide, glimepiride, glyburide) creates a three-layer hypoglycemia risk. If you fall into this category, rhodiola should be introduced only under direct physician supervision with daily glucose monitoring.

What to Tell Your Doctor

Bring the following to your next appointment:

1. The exact rhodiola product name, dose, and standardization (rosavins %, salidroside %)
2. How long you have been taking it or plan to start
3. Your recent fasting glucose and blood pressure readings
4. Any other supplements, especially those with glucose-lowering potential (berberine, cinnamon extract, alpha-lipoic acid, chromium)

Your physician may want to check a baseline metabolic panel and adjust your glucose monitoring frequency. If you are already taking both without problems, that history is useful information too.